Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient
Sana Biotechnology reported that its donor-derived islet cell therapy continued producing insulin for 14 months in one patient with Type 1 diabetes, with no safety concerns reported.
The company said its hypoimmune modified islets avoided immune detection for more than a year and maintained insulin production comparable to the first six months of the study, supported by sustained C-peptide levels even after mixed meal testing. Principal investigator Per-Ola Carlsson said, “This work suggests that the hypoimmune technology has the potential to enable a functional cure for type 1 diabetes without immunosuppression,” as Sana also plans to submit an IND for SC451, a stem cell-derived therapy based on the same platform.
The findings underscore Washington state’s growing leadership in cell therapy innovation, advancing toward scalable, one-time treatments for Type 1 diabetes.